Egypt: EIPICO’s consolidated profits leap 33% in 2024

Total net sales jumped by 45% to EGP 7.59 billion at the end of December 2024 from EGP 5.23 billion, according to the consolidated financial results

Staff Writer, Mubasher

March 3, 2025

PHOTO
A trader works at the Egyptian stock exchange in Cairo, Egypt September 23, 2019.Mohamed Abd El Ghany

Egyptian International Pharmaceutical Industries (EIPICO) logged net profits after tax worth EGP 1.09 billion in 2024, up 33% year-on-year (YoY) from EGP 823 million.

Total net sales jumped by 45% to EGP 7.59 billion at the end of December 2024 from EGP 5.23 billion, according to the consolidated financial results.

Listed on Egyptian Exchange (EGX) since September 1995, EIPICO operates within the pharmaceuticals, biotechnology, and life sciences sector focusing on pharmaceuticals.

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

ZAWYA NEWSLETTERS

RELATED ARTICLES

ZAWYA NEWSLETTERS

LATEST VIDEO